Publications by authors named "Gabriel Haas"

Claim this Profile
M
MyoQuant: An optimized image analysis algorithm for quantitative analysis of skeletal muscle fibers.
Josh Madsen, Gabriel Haas, Andrew Dunn, Natalia Ziemkiewicz, David Johnson

MethodsX· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, James L Bailen, Erik P M Roos, Gabriel P Haas

J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial.
Neal D Shore, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Gabriel P Haas

J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Gabriel P Haas

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354).
Chris Atzinger, Heather Dickerson, Ela Polek, Christiane Otto, Yanli Gao, Gabriel P Haas

JSLS· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, Arun A Azad, Ciara Conduit, Gabriel P Haas

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.
Arun A Azad, Daniel P Petrylak, Taro Iguchi, Neal D Shore, Arnauld Villers, Gabriel P Haas

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.
Ugo De Giorgi, Stephen J Freedland, Antti Rannikko, Miguel Ramirez-Backhaus, Arnauld Villers, Gabriel P Haas

Prostate Cancer Prostatic Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Gabriel P Haas

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.
Andrew J Armstrong, Arun A Azad, Ciara Conduit, Gabriel P Haas, Christopher Bland

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, Arun A Azad, Taro Iguchi, Gabriel P Haas

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.
Nima Sharifi, Arun A Azad, Mona Patel, Jason W D Hearn, Michele Wozniak, Gabriel P Haas

Cell Rep Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
Julie O'Neal, Matthew L Cooper, Julie K Ritchey, Susan Gladney, Jessica Niswonger, Gabriel J Haas

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto, Gabriel P Haas

N Engl J Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seasonal Trends in Emergency Department Visits for Mental and Behavioral Health Conditions Among Children and Adolescents Aged 5-17 Years - United States, January 2018-June 2023.
Lakshmi Radhakrishnan, Kelly Carey, Dylan Pell, Amy Ising, Danielle Brathwaite, Gabriel Ann Haas

MMWR Morb Mortal Wkly Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Andrew J Armstrong, Taro Iguchi, Arun A Azad, Arnauld Villers, Boris Alekseev, Gabriel P Haas

Eur Urol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-sectional Survey to Assess Awareness of Syndromic Surveillance by Clinicians Practicing Emergency Medicine: An Opportunity for Education and Collaboration.
Gabriel Ann Haas, Brittany Hudson-Walsh, Adrienne Malik, Kellie Wark

West J Emerg Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Gabriel P Haas

Prostate Cancer Prostatic Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Gabriel P Haas

Prostate· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
Julie O'Neal, Julie K Ritchey, Matthew L Cooper, Jessica Niswonger, L Sofía González, Gabriel J Haas

Leukemia· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Srinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, Pooja Manchandani, Nakyo Heo, Gabriel P Haas

Clin Transl Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Arun A Azad, Taro Iguchi, Russell Z Szmulewitz, Daniel P Petrylak, Gabriel P Haas

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laminin-111-Enriched Fibrin Hydrogels Enhance Functional Muscle Regeneration Following Trauma.
Natalia Ziemkiewicz, Genevieve M Hilliard, Andrew J Dunn, Josh Madsen, Gabriel Haas

Tissue Eng Part A· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, Russell Z Szmulewitz, Daniel P Petrylak, Gabriel P Haas

Prostate Cancer Prostatic Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
David F Penson, Andrew J Armstrong, Raoul S Concepcion, Neeraj Agarwal, Carl A Olsson, Gabriel P Haas

Prostate Cancer Prostatic Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis